This second study, designed to meet the FDA requirements for US registration, will examine patients between 51 and 80 years old suffering from painful symptoms of knee osteoarthritis.
Further, approximately half of all of the study participants have completed the final observation visit. Isolagen anticipates the acne study will conclude in the first quarter of 2009.
The current randomized, double-blind, placebo-controlled clinical study will enroll approximately 48 patients at one clinical trial site in Beverly Hills, California. Patients will be randomized to receive either
The first trial was a 24-week, open-labeled extension to a four-week double-blinded, pivotal trial that enrolled 308 patients. The second trial was a 48-week, open-labeled trial in 250
The study will be conducted at four clinical sites with 40 evaluable patients being enrolled. The first study site has been initiated and the company plans to initiate
The transaction is subject to regulatory review by competition authorities in the US and Europe, and is expected to complete by early 2009. John Clarke, president of GlaxoSmithKline
Mr Chereau was formerly the vice president and general manager of Genzyme Cardiovascular, a business unit within Genzyme in Cambridge. Mr Chereau also led Genzyme’s cardiovascular business development
All parties involved have agreed on the time line and conditions of this relocation, enabling a smooth transition to the new production facility, the company said. The new
Dr Leigh has previously served as chief medical officer for Paramount Biosciences. Dr Leigh has also held positions at Genentech, Idec Pharmaceuticals, and Biogen Idec where he was
Joint Replacement Instrumentation (JRI) will market its product, the Furlong H-AC hip stem, alongside Active Implants’s TriboFit acetabular system, the only soft bearing articulation product available. TriboFit employs
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.